217 related articles for article (PubMed ID: 15988036)
1. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
Ustach CV; Kim HR
Mol Cell Biol; 2005 Jul; 25(14):6279-88. PubMed ID: 15988036
[TBL] [Abstract][Full Text] [Related]
2. Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation.
Riehle KJ; Johnson MM; Johansson F; Bauer RL; Hayes BJ; Gilbertson DG; Haran AC; Fausto N; Campbell JS
Biochim Biophys Acta; 2014 Feb; 1842(2):318-25. PubMed ID: 24269585
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.
Hurst NJ; Najy AJ; Ustach CV; Movilla L; Kim HR
Biochem J; 2012 Feb; 441(3):909-18. PubMed ID: 22035541
[TBL] [Abstract][Full Text] [Related]
4. The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth.
Ehnman M; Li H; Fredriksson L; Pietras K; Eriksson U
Oncogene; 2009 Jan; 28(4):534-44. PubMed ID: 18997817
[TBL] [Abstract][Full Text] [Related]
5. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression.
Ustach CV; Taube ME; Hurst NJ; Bhagat S; Bonfil RD; Cher ML; Schuger L; Kim HR
Cancer Res; 2004 Mar; 64(5):1722-9. PubMed ID: 14996732
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator.
Fredriksson L; Ehnman M; Fieber C; Eriksson U
J Biol Chem; 2005 Jul; 280(29):26856-62. PubMed ID: 15911618
[TBL] [Abstract][Full Text] [Related]
7. PDGF-D activation by macrophage-derived uPA promotes AngII-induced cardiac remodeling in obese mice.
Cheng YW; Zhang ZB; Lan BD; Lin JR; Chen XH; Kong LR; Xu L; Ruan CC; Gao PJ
J Exp Med; 2021 Sep; 218(9):. PubMed ID: 34236404
[TBL] [Abstract][Full Text] [Related]
8. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.
Huang W; Fridman Y; Bonfil RD; Ustach CV; Conley-LaComb MK; Wiesner C; Saliganan A; Cher ML; Kim HR
Oncogene; 2012 Oct; 31(42):4527-35. PubMed ID: 22158043
[TBL] [Abstract][Full Text] [Related]
9. Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Najy AJ; Dyson G; Jena BP; Lin CY; Kim HR
Am J Physiol Cell Physiol; 2016 Feb; 310(4):C293-304. PubMed ID: 26157007
[TBL] [Abstract][Full Text] [Related]
10. A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
Ustach CV; Huang W; Conley-LaComb MK; Lin CY; Che M; Abrams J; Kim HR
Cancer Res; 2010 Dec; 70(23):9631-40. PubMed ID: 21098708
[TBL] [Abstract][Full Text] [Related]
11. Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.
Najy AJ; Won JJ; Movilla LS; Kim HR
Mol Cancer Res; 2012 Aug; 10(8):1087-97. PubMed ID: 22689130
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator is a potent activator of PDGF-CC.
Fredriksson L; Li H; Fieber C; Li X; Eriksson U
EMBO J; 2004 Oct; 23(19):3793-802. PubMed ID: 15372073
[TBL] [Abstract][Full Text] [Related]
13. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
14. T-cell lymphokines, interleukin-4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet-derived growth factor.
Wang W; Chen HJ; Giedd KN; Schwartz A; Cannon PJ; Rabbani LE
Circ Res; 1995 Dec; 77(6):1095-106. PubMed ID: 7586221
[TBL] [Abstract][Full Text] [Related]
15. PDGF-D Prodomain Differentially Inhibits the Biological Activities of PDGF-D and PDGF-B.
Li L; Wu D; Qin X; Mi LZ
J Mol Biol; 2022 Aug; 434(16):167709. PubMed ID: 35777468
[TBL] [Abstract][Full Text] [Related]
16. The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells.
Padró T; Mesters RM; Dankbar B; Hintelmann H; Bieker R; Kiehl M; Berdel WE; Kienast J
J Cell Sci; 2002 May; 115(Pt 9):1961-71. PubMed ID: 11956327
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Unlü A; Leake RE
Int J Biol Markers; 2003; 18(2):147-51. PubMed ID: 12841684
[TBL] [Abstract][Full Text] [Related]
18. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
19. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Lyon PB; See WA; Xu Y; Cohen MB
Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
